Traveler's Diarrhea - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Traveler's Diarrhea - Pipeline Review, H2 2016

Traveler's Diarrhea - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Traveler's Diarrhea - Pipeline Review, H2 2016
Published Aug 31, 2016
54 pages — Published Aug 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Traveler's Diarrhea - Pipeline Review, H2 2016, provides an overview of the Traveler's Diarrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Traveler's Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traveler's Diarrhea and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Traveler's Diarrhea
- The report reviews pipeline therapeutics for Traveler's Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Traveler's Diarrhea therapeutics and enlists all their major and minor projects
- The report assesses Traveler's Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Traveler's Diarrhea

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Traveler's Diarrhea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by und

  
Source:
Document ID
GMDHC8427IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Traveler's Diarrhea Overview71
Therapeutics Development82
  Pipeline Products for Traveler's Diarrhea Overview81
  Pipeline Products for Traveler's Diarrhea Comparative Analysis91
Traveler's Diarrhea Therapeutics under Development by Companies101
Traveler's Diarrhea Therapeutics under Investigation by Universities/Institutes111
Traveler's Diarrhea Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Traveler's Diarrhea Products under Development by Companies151
Traveler's Diarrhea Products under Investigation by Universities/Institutes161
Traveler's Diarrhea Companies Involved in Therapeutics Development176
  Cosmo Pharmaceuticals NV171
  GlaxoSmithKline Plc181
  Nippon Shinyaku Co., Ltd.191
  Prokarium Limited201
  Scandinavian Biopharma Holding AB211
  Sigmoid Pharma Limited221
Traveler's Diarrhea Therapeutics Assessment239
  Assessment by Monotherapy Products231
  Assessment by Target242
  Assessment by Mechanism of Action262
  Assessment by Route of Administration282
  Assessment by Molecule Type302
Drug Profiles3212
  Etvax Drug Profile322
  GVXNSD-133 Drug Profile341
  IMSUTMR-1501 Drug Profile351
  prulifloxacin Drug Profile362
  rifamycin CR Drug Profile382
  Typhetec Drug Profile401
  Vaccine for Traveler's Diarrhea Drug Profile411
  Vaccine for Traveler's Diarrhea Drug Profile421
  Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea Drug Profile431
Traveler's Diarrhea Dormant Projects441
Traveler's Diarrhea Discontinued Products451
Traveler's Diarrhea Product Development Milestones467
  Featured News &Press Releases461
    Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX461
    Oct 04, 2013: Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers Diarrhea461
    Sep 11, 2012: Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers' Diarrhea471
    Sep 14, 2009: Data From Optimers Second Phase III Study of Prulifloxacin Presented At Annual Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC)481
    Sep 02, 2009: Optimer Pharmaceuticals Announces Presentations Of Additional Phase III Prulifloxacin Data At Upcoming ICAAC Annual Meeting491
    Feb 26, 2009: Optimer Pharmaceuticals Announces Publication In Peer-Reviewed Journal About Prulifloxacins Antibacterial Activity Against Infectious Diarrhea Producing Bacteria491
    Feb 24, 2009: Optimer Pharmaceuticals Announces Positive Results From Second Phase III Study Of Prulifloxacin For Infectious Diarrhea In Travelers501
    Oct 20, 2008: Data from Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea Presented At ICAAC/IDSA Annual Meeting511
    Sep 02, 2008: Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase III Clinical Trial511
    Jul 16, 2008: Optimer Pharmaceuticals Announces Positive Results In Prulifloxacin Phase III Study521
    Mar 11, 2008: Optimer Pharmaceuticals Completes Enrollment In Phase III Clinical Trial Of Prulifloxacin In Patients with Travelers Diarrhea521
Appendix532
  Methodology531
  Coverage531
  Secondary Research531
  Primary Research531
  Expert Panel Validation531
  Contact Us531
  Disclaimer541

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Traveler's Diarrhea - Pipeline Review, H2 2016" Aug 31, 2016. Alacra Store. May 14, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Traveler-s-Diarrhea-Pipeline-Review-H2-2016-2088-16510>
  
APA:
Global Markets Direct - Market Research. (2016). Traveler's Diarrhea - Pipeline Review, H2 2016 Aug 31, 2016. New York, NY: Alacra Store. Retrieved May 14, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Traveler-s-Diarrhea-Pipeline-Review-H2-2016-2088-16510>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.